Head and Neck Squamous Cell Carcinoma

Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility

By MedXY 09/07/2026

Tissue-informed circulating tumor DNA assays demonstrate high detection rates and exceptional sensitivity and specificity in monitoring HPV-positive and HPV-negative head and neck squamous cell carcinoma, supporting their clinical utility in disease management.

news Oncology Otorhinolaryngology

Enhanced Pathologic Response in Head and Neck Squamous Cell Carcinoma with Neoadjuvant Chemoimmunotherapy

By MedXY 08/25/2026

Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.

AI Oncology Pathology & Lab Medicine

Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer

By MedXY 10/24/2025

This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.

Clinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

By MedXY 09/04/2025

A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.